[{"id":"38d14a85-f7dd-4762-9bf5-4da0e8be0e8f","acronym":"KEYMAKER-U04 Substudy","url":"https://clinicaltrials.gov/study/NCT05845814","created_at":"2023-05-06T15:04:43.804Z","updated_at":"2025-02-25T15:28:00.798Z","phase":"Phase 1/2","brief_title":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","source_id_and_acronym":"NCT05845814 - KEYMAKER-U04 Substudy","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 06/23/2023","start_date":" 06/23/2023","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2025-02-10"},{"id":"9f8d313e-74c9-44df-85b7-d0e225eab089","acronym":"KEYSTEP-008","url":"https://clinicaltrials.gov/study/NCT04895722","created_at":"2021-05-20T11:54:07.770Z","updated_at":"2024-07-02T16:34:59.923Z","phase":"Phase 2","brief_title":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)","source_id_and_acronym":"NCT04895722 - KEYSTEP-008","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS wild-type","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 06/25/2021","start_date":" 06/25/2021","primary_txt":" Primary completion: 10/20/2025","primary_completion_date":" 10/20/2025","study_txt":" Completion: 11/18/2025","study_completion_date":" 11/18/2025","last_update_posted":"2024-05-30"},{"id":"b7ba04ad-2e05-4858-90e2-5ecabf721773","acronym":"KeyImPaCT","url":"https://clinicaltrials.gov/study/NCT03516981","created_at":"2021-01-18T17:18:40.896Z","updated_at":"2024-07-02T16:35:17.597Z","phase":"Phase 2","brief_title":"A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)","source_id_and_acronym":"NCT03516981 - KeyImPaCT","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • favezelimab (MK-4280) • quavonlimab (MK-1308) • favezelimab/pembrolizumab (MK-4280A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 06/28/2025","primary_completion_date":" 06/28/2025","study_txt":" Completion: 06/28/2025","study_completion_date":" 06/28/2025","last_update_posted":"2024-02-26"}]